<DOC>
	<DOCNO>NCT00526890</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Selenomethionine may slow growth tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together selenomethionine radiation therapy may kill tumor cell . PURPOSE : This phase II trial study side effect well selenomethionine work give together carboplatin , paclitaxel , radiation therapy treat patient stage III non-small cell lung cancer remove surgery .</brief_summary>
	<brief_title>Carboplatin , Paclitaxel , Selenomethionine , Radiation Therapy Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability selenomethionine combination chemotherapy radiotherapy patient unresectable stage IIIA IIIB non-small cell lung cancer . - Determine incidence excessive adverse event , form esophagitis , pneumonitis , myelosuppression , reduce regimen . Secondary - Estimate response rate , failure-free survival , overall survival patient . - Correlate selenium level degree observe adverse event . OUTLINE : This multicenter study . Patients receive oral selenomethionine twice daily 1 week daily 6 week . Patients also receive paclitaxel IV 1 hour weekly carboplatin IV 30 minute weekly 6 week undergo radiotherapy 5 day week 6 week . Treatment continue absence disease progression unacceptable toxicity . Blood sample collect baseline weekly treatment analyze absorption spectrophotometry selenium measurement drug concentration After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) , include follow histologic subtypes : Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell carcinoma ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Stage IIIA disease OR select stage IIIB disease T12 , N2 disease OR T3 , N2 T4 , N0N2 disease ( base tumor closeness carina , invasion mediastinum , invasion chest wall ) Contralateral mediastinal disease ( N3 ) allow gross disease encompass radiation boost field Tumors adjacent vertebral body allow unless demonstrable bone invasion All gross disease must able encompassed radiation boost field No direct invasion vertebra body Unresectable inoperable disease Measurable disease Suitable radiotherapy , deem radiation oncologist No scalene , supraclavicular , contralateral hilar node involvement Pleural effusion allow provided transudate , cytologically negative , nonbloody , , accord radiation oncologist , tumor encompass within reasonable radiation field Pleural effusion see chest CT scan , chest xray , small tap allow No exudative , bloody , cytologically malignant effusion No know brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ Total bilirubin ≤ 1.5 mg/dL Creatinine normal Alkaline phosphatase AND AST ALT meet 1 follow criterion : Alkaline phosphatase normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 5 time ULN AND AST ALT normal Able swallow oral medication No peripheral neuropathy &gt; grade 1 No history allergic reaction attribute compound similar chemical biologic composition selenomethionine agent formulate Cremophor EL No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Clinically significant cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No currently `` active '' second malignancy nonmelanoma skin cancer Patients consider `` active '' malignancy complete therapy consider physician less 30 % risk relapse Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 2 week since prior formal exploratory thoracotomy ( N2 node identify make patient ineligible surgery ) No prior chemotherapy radiotherapy NSCLC No prior taxanes platinum drug No concurrent investigational agent anticancer therapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent chemotherapy hormonal therapy , except follow : Steroids administer adrenal failure septic shock Hormones administer nondiseaserelated condition ( e.g. , insulin diabetes ) Glucocorticosteroids administer antiemetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>